Medical Access and Reimbursement in Denmark

Psilocybin and psilocin, including psilocybin-containing mushrooms and spores, are controlled on Denmark's List B. Lawful access outside ordinary prescription medicine is limited to authorised scientific or medical use; current Danish psilocybin activity is research, including alcohol use disorder, cluster headache and PsyPal. # # # # #

MDMA is controlled on List B. No routine Danish medical or reimbursement pathway was identified outside authorised trials or special permissions. # #

Spravato is EU-authorised. In November 2025 Medicinraadet recommended it for adults with moderate-to-severe treatment-resistant depression after at least three failed antidepressant treatments in the current episode; it had already been recommended for admitted patients with acute suicidal risk. Delivery still requires supervised clinical use and defined start-stop criteria. # # # #

Ketamine is controlled on List B and has established medical use, but no dedicated national reimbursement route for antidepressant ketamine was identified. It should be separated from Spravato's authorised esketamine pathway. # #

DMT is controlled on Denmark's List B. No authorised routine medical or reimbursement route was identified in reviewed sources. #

5-MeO-DMT is controlled on Denmark's List B. Reviewed sources did not show a Danish patient-access or reimbursement route. #

Ibogaine is controlled on Denmark's List B. No routine treatment or reimbursement pathway was identified. #

The older grey-area framing should not be used as access language. Denmark controls DMT, and no ceremonial, community-use or medical reimbursement route for ayahuasca was identified in official sources. # #

Mescaline is controlled on Denmark's List B. No routine medical or reimbursement route was identified. #

2C-family access should be treated as controlled-substance territory rather than a care pathway. Reviewed Danish sources did not show authorised medical access or reimbursement. # #